Paid Clinical Trials Kentucky
Discover 967 paid clinical trials in Kentucky. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
GENOCARE: a Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual CareGENOCARE: a Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
Sponsor:
Reema A. Patel
Location:
Code:
NCT05391126
Conditions
Colorectal Cancer
Pancreatic Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Irinotecan
A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults with Thyroid Eye Disease.A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults with Thyroid Eye Disease.
Sponsor:
argenx
Location:
Code:
NCT06307626
Conditions
Thyroid Eye Disease
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Efgartigimod PH20 SC
Placebo PH20 SC
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic MigraineA Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT04616326
Conditions
Chronic Migraine
Eligibility Criteria
Sex: All
Age: 12 - 17
Healthy Volunteers: Not accepted
Interventions
Galcanezumab
Placebo
Behavioral Effects of Drugs Inpatient 44 Neurobehavioral Mechanisms of Opioid ChoiceBehavioral Effects of Drugs Inpatient 44 Neurobehavioral Mechanisms of Opioid Choice
Sponsor:
Joshua A. Lile, Ph.D.
Location:
Code:
NCT06312657
Conditions
Opioid Use Disorder
Eligibility Criteria
Sex: All
Age: 18 - 50
Healthy Volunteers: Not accepted
Interventions
Drug Cue
Money
Withdrawal
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT05026866
Conditions
Alzheimer Disease
Eligibility Criteria
Sex: All
Age: 65 - 70+
Healthy Volunteers: Not accepted
Interventions
Donanemab
Placebo
Primary Subtalar Arthrodesis for Calcaneal FracturesPrimary Subtalar Arthrodesis for Calcaneal Fractures
Sponsor:
Wake Forest University Health Sciences
Location:
Code:
NCT06249126
Conditions
Calcaneus Fracture
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Primary Fusion (Open Reduction Internal Fixation (ORIF) + Primary Subtalar Arthrodesis (PSTA)
Open Reduction Internal Fixation (ORIF) only
Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy AloneEffectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone
Sponsor:
Introgen Therapeutics
Location:
Code:
NCT00041626
Conditions
Carcinoma, Squamous Cell
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
INGN 201
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDACA Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
Sponsor:
Genentech, Inc.
Location:
Code:
NCT05968326
Conditions
Adenocarcinoma, Pancreatic Ductal
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Autogene cevumeran
Atezolizumab
mFOLFIRINOX
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor:
NRG Oncology
Location:
Code:
NCT05879926
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ovarian Function Suppression + Aromatase Inhibitor
Adjuvant Chemotherapy + Ovarian Function Suppression
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade GliomaA Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT03871257
Conditions
Low Grade Glioma
Neurofibromatosis Type 1
Visual Pathway Glioma
Eligibility Criteria
Sex: All
Age: 2 - 21
Healthy Volunteers: Not accepted
Interventions
Carboplatin
Magnetic Resonance Imaging
Quality-of-Life Assessment
Questionnaire Administration
Selumetinib Sulfate